Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Heart transplantation: secondary prevention].

E Nellessen1, P Lancellotti, J C Demoulin

  • 1Service de Cardiologie, CHU de Liège.

Revue Medicale De Liege
|August 30, 2003
PubMed
Summary

This review covers immunosuppressive therapy after heart transplantation, detailing drug classes, side effects, rejection types, infections, and cancer risks for improved patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac angiosarcoma.

Acta cardiologica·2025
Same author

Comments on association of HbA1c with carotid artery plaques in patients with coronary heart disease.

Acta cardiologica·2023
Same author

[A new approach in coronary interventional cardiology: the distal radial approach].

Revue medicale de Liege·2022
Same author

[Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].

Revue medicale de Liege·2022
Same author

[Tricuspid regurgitation: transcatheter treatment by TriClip®].

Revue medicale de Liege·2022
Same author

[Heart failure with preserved ejection fraction (HFpEF). What's up?]

Revue medicale de Liege·2022

Area of Science:

  • Cardiology
  • Immunology
  • Transplantation Medicine

Background:

  • Cardiac transplantation is the primary treatment for end-stage heart failure.
  • Immunosuppressive therapy is crucial in the perioperative period to prevent graft rejection.

Purpose of the Study:

  • To review immunosuppressive agents used in cardiac transplantation.
  • To discuss graft rejection types, associated infections, and cancer risks.

Main Methods:

  • Literature review of immunosuppressive agents (calcineurin inhibitors, anti-metabolites, corticosteroids).
  • Discussion of general preventive measures and types of rejection (hyperacute, acute vascular, acute cellular, chronic).
  • Overview of common infections (bacterial, protozoan, fungal, viral) and cancer risks (skin tumors, non-Hodgkin lymphomas).

Main Results:

  • Key immunosuppressive drug classes and their side effects are outlined.
  • Different forms of graft rejection and preventive strategies are detailed.
  • Infectious complications and oncological risks post-transplant are described.

Conclusions:

  • Effective immunosuppression management is vital for successful cardiac allograft survival.
  • Monitoring for infections and malignancies is essential for long-term patient health.
  • Comprehensive understanding of immunosuppression, rejection, and complications guides clinical practice.

Related Experiment Videos